SecBot SecBot
Biotech Drug Report Generated Sep 11, 2026

imdusiran

ABUS·Arbutus Biopharma Corp
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2 (completed); Phase 2b planned
Time to market
Unknown, likely several years out. Phase 2b design is FDA-aligned but the trial had not been initiated as of the Aug 2026 update; a registrational Phase 3 and filing would still follow, so 2028+ at the earliest if all goes well.
Why 3/10
No hard, dated binary catalyst for imdusiran in the next ~12 months: the Phase 2 study is complete, Phase 2b is FDA-aligned but not yet initiated (per Aug 2026 Q2 earnings), and no PDUFA or scheduled topline readout exists, so the drug itself is not a near-term share-price event (score capped at 5, set at 3 given the company's near-term value is dominated by the tender offer and LNP litigation).
Actionable Insight NEUTRAL

Near-term share-price drivers are the $230M Dutch-auction tender offer (expires Sept 29, 2026, at $5.00–$5.75) and the LNP patent lawsuits vs. Pfizer/BioNTech; watch for Phase 2b initiation announcements and conference data updates for imdusiran specifically.

Price Chart

Loading chart...

Executive Summary

Imdusiran (development code AB-729) is Arbutus Biopharma's (Nasdaq: ABUS) lead clinical asset, an RNA-interference drug for chronic hepatitis B designed to knock down viral surface antigen and, combined with standard antivirals plus pegylated interferon, drive "functional cure." Its Phase 2 open-label study (NCT04980482, ~43 patients) is complete with results, the FDA granted Fast Track designation in April 2026, and Arbutus said in Q2 2026 earnings (Aug 2026) that it had achieved FDA alignment on the Phase 2b trial design. However, the drug has no hard, dated binary catalyst within 12 months, Phase 2b is not yet enrolling and no topline readout or regulatory decision is scheduled, and near-term stock drivers (a $230M tender offer expiring Sept 29, 2026, and LNP patent litigation versus Pfizer/BioNTech funded by a $950M Moderna settlement) are corporate, not this molecule.

How It Works

Imdusiran is a type of gene-silencing drug (RNA interference) given by injection under the skin. It carries a short piece of RNA that finds and destroys the genetic messages the hepatitis B virus uses to make its proteins, especially the viral surface antigen that keeps the immune system from clearing the infection. The idea is to combine imdusiran with standard oral hepatitis B antivirals plus an immune-stimulating interferon shot so the patient's own immune system can then achieve a durable "functional cure", a sustained loss of detectable surface antigen after stopping therapy.

Trial Status

The Phase 2 open-label study of AB-729 (imdusiran) + nucleos(t)ide analogue + pegylated interferon alfa-2a (NCT04980482, ~43 patients, Arbutus-sponsored) is COMPLETED with results, primary completion March 2025, study completion May 2025. Arbutus reported 10 patients achieving functional cure across its HBV program (March 2026 update), FDA granted Fast Track designation for chronic hepatitis B on April 15, 2026, and Q2 2026 earnings (Aug 2026) stated FDA alignment was achieved on the Phase 2b trial design, which has not yet been initiated.

The Two-Sided Case

▲ Bull Case5
Completed Phase 2 open-label study (NCT04980482) of AB-729 + nucleos(t)ide analogue + pegylated interferon in chronic hepatitis B, COMPLETED with results, ~43 patients, primary completion Mar 2025 (local ClinicalTrials.gov record).
Company reported 'functional cures' in its HBV program, March 2026 update said two more patients achieved functional cure, bringing the total to 10.
Regulatory momentum: FDA granted Fast Track designation for imdusiran in chronic hepatitis B (April 15, 2026; stock +7.59% 1-day around that catalyst), and FDA alignment on Phase 2b trial design confirmed in Q2 2026 earnings.
Well-funded to run the program: $178.4M Moderna settlement payment received July 2026 and $92.6M cash at June 30, 2026, plus a $230M share-repurchase tender offer, reducing near-term dilution risk for the clinical pipeline.
Analyst consensus constructive: 3 Strong Buy / 3 Buy / 1 Hold, with mean price target $5.51 vs. $5.12 close (single-analyst snapshot, ~7.7% implied upside).
▼ Bear Case5
No hard, dated binary for imdusiran in the next 12 months: the Phase 2 study is complete, Phase 2b is FDA-aligned but not yet initiated per Q2 2026 earnings (Aug 2026), and no PDUFA/readout date is on the calendar.
Drug efficacy unproven at registrational scale, functional-cure rates reported by the company (10 patients in its HBV program per March 2026 update) remain modest and are not a Phase 3-proven endpoint.
Market skepticism visible in positioning: FINRA daily short-volume ratio hit 75.1% on 2026-09-10 (signal 'elevated'), and semi-monthly short interest was 18.9M shares, ~9.56% of estimated shares outstanding (3.08 days to cover) as of 2026-08-31.
Institutional investors were two-sided in Q2 2026 13Fs: Morgan Stanley trimmed -31.6% and Adage Capital exited, offsetting accumulation by Goldman Sachs (+218.7%) and D.E. Shaw (+166.7%).
Clinical-stage company with no approved products, operating cash burn continues (~$14.1M in H1 2026 per Q2 8-K analysis), and stock value is increasingly tied to litigation/tender offer rather than this drug.

Upcoming Catalysts

  • Phase 2b trial initiation and enrollment updates for imdusiran (no fixed date announced)
  • Conference/data presentations on Phase 2 functional-cure results
  • Q3 2026 earnings update (likely Oct/Nov 2026), pipeline and Phase 2b timing
  • Corporate (non-drug) events that will move ABUS: $230M Dutch-auction tender offer expires Sept 29, 2026, and LNP patent litigation vs. Pfizer/BioNTech progresses

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Arbutus Biopharma Corp 8-K ABUS ·Originating report

Sources · 7

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 globenewswire.com6 globenewswire.com7 globenewswire.com